AXNX Axonics Inc

Price (delayed)

$57.66

Market cap

$2.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.28

Enterprise value

$2.65B

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of BulkamidĀ®, offers ...

Highlights
AXNX's gross profit has surged by 71% year-on-year and by 16% since the previous quarter
The revenue has surged by 52% year-on-year and by 14% since the previous quarter
AXNX's quick ratio is down by 34% year-on-year and by 3.1% since the previous quarter

Key stats

What are the main financial stats of AXNX
Market
Shares outstanding
49.96M
Market cap
$2.88B
Enterprise value
$2.65B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.01
Price to sales (P/S)
9.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.69
Earnings
Revenue
$273.7M
EBIT
-$59.88M
EBITDA
-$48.16M
Free cash flow
$968,000
Per share
EPS
-$1.28
Free cash flow per share
$0.02
Book value per share
$11.51
Revenue per share
$5.86
TBVPS
$10.25
Balance sheet
Total assets
$659.35M
Total liabilities
$89.21M
Debt
$9.12M
Equity
$570.14M
Working capital
$399.83M
Liquidity
Debt to equity
0.02
Current ratio
7.13
Quick ratio
6.16
Net debt/EBITDA
4.77
Margins
EBITDA margin
-17.6%
Gross margin
72.2%
Net margin
-21.8%
Operating margin
-23.7%
Efficiency
Return on assets
-10.2%
Return on equity
-11.8%
Return on invested capital
-43.4%
Return on capital employed
-10.1%
Return on sales
-21.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXNX stock price

How has the Axonics stock price performed over time
Intraday
-4.8%
1 week
7.88%
1 month
1.3%
1 year
-1.17%
YTD
-7.79%
QTD
-7.79%

Financial performance

How have Axonics's revenue and profit performed over time
Revenue
$273.7M
Gross profit
$197.67M
Operating income
-$64.95M
Net income
-$59.7M
Gross margin
72.2%
Net margin
-21.8%
AXNX's gross profit has surged by 71% year-on-year and by 16% since the previous quarter
The revenue has surged by 52% year-on-year and by 14% since the previous quarter
The company's net margin has surged by 51% YoY and by 31% QoQ
The operating margin is up by 40% year-on-year and by 28% since the previous quarter

Growth

What is Axonics's growth rate over time

Valuation

What is Axonics stock price valuation
P/E
N/A
P/B
5.01
P/S
9.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.69
AXNX's EPS is up by 31% year-on-year and by 22% since the previous quarter
AXNX's equity is up by 18% year-on-year and by 3.8% since the previous quarter
The P/B is 12% below the 5-year quarterly average of 6.0 and 12% below the last 4 quarters average of 6.0
The price to sales (P/S) is 87% lower than the 5-year quarterly average of 77.1 and 19% lower than the last 4 quarters average of 12.7
The revenue has surged by 52% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Axonics business performance
AXNX's ROS is up by 45% year-on-year and by 32% since the previous quarter
AXNX's ROIC is up by 34% QoQ and by 29% YoY
The ROE has increased by 33% YoY and by 24% from the previous quarter
AXNX's ROA is up by 32% YoY and by 25% from the previous quarter

Dividends

What is AXNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXNX.

Financial health

How did Axonics financials performed over time
Axonics's current ratio has decreased by 40% YoY and by 3.5% from the previous quarter
The total liabilities is up by 36% year-on-year and by 8% since the previous quarter
The company's debt is 98% lower than its equity
AXNX's equity is up by 18% year-on-year and by 3.8% since the previous quarter
The company's debt fell by 12% YoY and by 3.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.